- 542studies on this subject, of 27,380 in the library
- 526peer-reviewed
- 1991–2026years published
- 54median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study.
The 20 highest-scoring studies
-
Sleep Architecture, Obstructive Sleep Apnea, and Cognitive Function in Adults
This consortium study investigated how sleep architecture and obstructive sleep apnea relate to cognitive function across five population-based cohorts. It examines associations with cognition but does not test whether treating sleep problems prevents dementia.
-
UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
UK Biobank is a large prospective study with over 500,000 participants that collects extensive health data and is openly available to researchers. It provides a resource for studying the causes of complex diseases of middle and old age, including Alzheimer's.
- Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study
-
Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness
This study tested Random Forest classifiers using structural MRI measures for detecting and predicting Alzheimer's disease, including how robust they are across cohorts. It is about computer-aided diagnosis, not about treating, curing or preventing the disease.
-
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
This study tested whether plasma neurofilament light identifies asymptomatic carriers of familial frontotemporal lobar degeneration mutations at risk of disease progression. It is observational and does not provide a treatment or cure.
-
Association between metabolic syndrome and risk of incident dementia in UK Biobank
In this large UK Biobank cohort, having metabolic syndrome was associated with a higher risk of developing dementia over 15 years of follow-up. This identifies metabolic syndrome as a risk factor that could be targeted, but the study did not test whether treating it prevents dementia.
-
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
In 437 people without dementia from the ADNI research study, researchers measured amyloid in spinal fluid (CSF amyloid-β42) and on florbetapir PET brain scans, then repeated the PET scan after an average of 2.1 years. They asked whether either test picks up abnormal amyloid buildup before the other; the study's title reports that the spinal fluid test does, but the summary held here gives no figures for how much earlier. It is a study about the timing of tests, not about treatment, and it does not show who will go on to develop dementia.
-
Association of Cardiovascular Health With Life Expectancy Free of Cardiovascular Disease, Diabetes, Cancer, and Dementia in UK Adults
This study quantified how levels of cardiovascular health relate to life expectancy free of major chronic disease, including dementia, in UK adults. It is observational, so it cannot show that improving cardiovascular health prevents dementia.
-
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology
This study found an association between the ABCC9 gene and hippocampal sclerosis of aging, a brain disease in the elderly. It is a genetic association study, so it does not show that changing this gene would treat or prevent the disease.
-
Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities
This genetic study found that periventricular and deep white matter hyperintensities have different genetic underpinnings. It is observational and does not test any treatment, cure or prevention for dementia.
-
Cerebrovascular risk factors impact frontoparietal network integrity and executive function in healthy ageing
In 22,059 healthy UK Biobank participants, people with more cerebrovascular risk factors had worse cognitive abilities. Statistical modelling linked that risk to reduced grey matter and white matter integrity in a fronto-parietal brain network that supports executive function (planning, switching and controlling attention). This is an observational association in people without dementia. It does not show that lowering vascular risk prevents Alzheimer's disease.
-
The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE)
This study combined data from 38,537 people across six population-based cohorts to examine how APOE genotypes, particularly the less common APOE-ε2 allele, relate to survival. The APOE-ε4 allele was already known to increase risks of Alzheimer's disease and mortality, but the effect of APOE-ε2 on diseases in the elderly and survival was less clear.
-
Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease
This genome-wide interaction study in 678 Alzheimer's Disease Neuroimaging Initiative participants looked for genetic factors that modify the relationship between brain beta-amyloid burden and cognitive impairment. The authors note that beta-amyloid is necessary for the pathologic diagnosis of Alzheimer's disease but is not sufficient to cause dementia.
-
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results
This first-in-human phase 1/2 trial tested PR006, an investigational gene therapy delivering the granulin gene using an AAV9 vector, in patients with frontotemporal dementia caused by GRN mutations. Non-clinical studies showed the therapy transduced patient-derived neurons and improved pathologies in mice, and the trial is ongoing to assess safety and tolerability.
-
The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study
This study assessed how the APOE gene and 23 other genetic variants affect the cumulative risk and age at which Alzheimer's disease and dementia begin, in a community-based cohort. Understanding genetic risk may help identify people at higher risk, but it does not provide a treatment or cure.
-
Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia
This study tested whether blood-based DNA methylation measures of biological aging are associated with cognitive impairment and dementia using data from two large cohort studies. It examines a possible link between aging measures and dementia but does not test any treatment, cure, or prevention.
-
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
This article reviews papers from the Alzheimer's Disease Neuroimaging Initiative, a long-running study that collects clinical, imaging, genetic and biochemical markers to detect and track Alzheimer's disease early. Its main contribution is to research tools and biomarkers, not a treatment or cure.
-
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
This study evaluated whether plasma GFAP and NfL levels predict dementia in UK Biobank participants. It is observational and does not show that measuring these markers or acting on them prevents dementia.
-
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
This review assessed how accurately ¹⁸F-FDG PET detects which people with mild cognitive impairment will later convert to Alzheimer's disease dementia or other dementias. It is about diagnosis, not treatment, cure or prevention.
-
Estimating Dementia Risk Using Multifactorial Prediction Models
This study evaluated how useful four widely used dementia risk scores are for estimating a person's 10-year risk of developing dementia. The results help clarify whether these tools add value in clinical practice, but they do not prevent or treat dementia.
See all 542 studies in Long-term cohort studies, with filters →
Newest additions on this subject
- Ultra-sensitive Mapping of Cell-free DNA-derived Methylomes Reveals Brain-specific Epigenetic Alterations Implicated in Alzheimer’s Disease
- Interpretable Phenotype Discovery Using Temporal Risk-Aware Clustering
- The transition to retirement and dementia risk: An application of sequence analysis
- A Pipeline for ADNI Resting-State Functional MRI Processing and Quality Control
- Tissue- and compartment-resolved brain age reveals vascular-metabolic and neurodegenerative aging
- A 2-Level Stacking Ensemble Framework for Multi-Class Alzheimer’s Disease Diagnosis Using CNN Feature Extractors and SVM-XGBoost Classifiers
- Unlocking Sensitive Data with SPHERE in the Age of AI
- Alzheimer disease risk estimates lose clinical calibration across study phases despite useful patient ranking
- Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimer’s disease
- A Spanish grammaticality judgment task for neurodegenerative diseases: inflectional, transitivity, and word order comprehension in PPA and Alzheimer's Disease
All 542 studies in Long-term cohort studies, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 526 |
| Preprint — not yet peer-reviewed | 15 |
| Retracted — do not rely on it | 1 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| moderate | 265 |
| low | 251 |
| high | 17 |
| not rated | 9 |
Most frequent journals
| Journal | Studies |
|---|---|
| Neurology | 41 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 34 |
| Journal of Alzheimer's disease : JAD | 18 |
| Stroke | 15 |
| NeuroImage | 13 |
| Alzheimer's research & therapy | 12 |
| JAMA neurology | 11 |
| Alzheimer s & Dementia | 10 |
| Neurobiology of aging | 10 |
| JAMA network open | 9 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 29 | |
| 2025 | 69 | |
| 2024 | 14 | |
| 2023 | 33 | |
| 2022 | 51 | |
| 2021 | 42 | |
| 2020 | 44 | |
| 2019 | 33 | |
| 2018 | 36 | |
| 2017 | 30 | |
| 2016 | 17 | |
| 2015 | 22 | |
| 2014 | 20 | |
| 2013 | 12 | |
| 2012 | 16 | |
| 2011 | 8 | |
| 2010 | 10 | |
| 2009 | 5 | |
| 2008 | 1 | |
| 2007 | 12 | |
| 2006 | 7 | |
| 2005 | 7 | |
| 2004 | 3 | |
| 2003 | 2 | |
| 2002 | 1 | |
| 2001 | 5 | |
| 2000 | 3 | |
| 1999 | 2 | |
| 1998 | 1 | |
| 1997 | 3 | |
| 1994 | 2 | |
| 1991 | 2 |
Counts the 542 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Inflammation and the immune system
- Tau biomarkers
- Brain tissue and pathology
- Drug development
- Hippocampus size on brain scans